Latest Breaking News On - Chinj cancer - Page 1 : vimarsana.com

Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer

Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Yang shiSacituzumab govitecan hziyEverest medicinesGreater chinaChief medical officerChinj cancer

Trial PROSPERs China s fight against advancing prostate cancer

Trial PROSPERs China’s fight against advancing prostate cancer New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer, Peter Doyle reports It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most populous country for patients with advanced prostate cancer, China’s medicine regulator, the National Medical Products Administration (NMPA), approved the oral androgen-receptor inhibitor enzalutamide for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.

United statesHiroshi hamaguchiAndrew krivoshikPeter doyleChinese journal of cancer researchFirst university hospitalOncology developmentChina national cancer registration instituteNational medical products administrationNational urological cancer centerPeking first university hospitalEfficacy studyChinese journalCancer researchChinj cancerSenior vice president